Metraipolis › archive › dc_c5033e475261

First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular… — Europe PMC PMID:41169385

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41169385
DOI
10.3389/fimmu.2025.1667793
License (as archived)
solo-consultazione
Archived
2026-11-09T07:23:32.793Z
SHA-256 of the archived text
bcb8a9a1f9317c956da9699bb5c4d44bdd87f3ed096e79688d8c1dd607c911aa
Stable URL of this page
https://metraipolis.com/documento/dc_c5033e475261

How to cite

First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular… — Europe PMC PMID:41169385 — Europe PMC (en), https://europepmc.org/article/MED/41169385 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c5033e475261 (Metraipolis archive dc_c5033e475261, sha256 bcb8a9a1f9317c956da9699bb5c4d44bdd87f3ed096e79688d8c1dd607c911aa)
BibTeX
@misc{dcc5033e475261,
  title = {First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular… — Europe PMC PMID:41169385},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41169385},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c5033e475261; sha256 bcb8a9a1f9317c956da9699bb5c4d44bdd87f3ed096e79688d8c1dd607c911aa},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41169385. Agents can read the archived copy with the MCP tool read_document.